Myeloma: Diagnosis and Management Source: National Institute for Health and Care Excellence

Myeloma: Diagnosis and Management Source: National Institute for Health and Care Excellence https://reference.medscape.com/cc2/p10/myeloma-diagnosis-and-management-secondary-care-2022a10022bp?ecd=WNL_drugguide_260203_MSCPREF_onc_etid8073926&uac=148436CN&impID=8073926 This Medscape summary of National Institute for Health and Care Excellence (NICE) guidance covers the diagnosis and management of myeloma (including smouldering myeloma and primary plasma cell leukaemia) in people aged 16 and over. It aims to improve care for people with myeloma by promoting the most effective tests and treatments for myeloma and its complications. This summary is intended for use by oncologists. NICE has a suite of technology appraisal guidance on myeloma either published or in development. These published technology appraisals cover NICE's position in relation to primary disease treatment, salvage therapy for relapsed myeloma and consolidation/maintenance therapy after primary management. The recommendations in this guideline complement the existing technology appraisals, giving further guidance in addition to the technology appraisals where myeloma-related subgroups are not included.